Fig 1.
Flow chart showing the selection of the study population from the PHDC routine health data.
Table 1.
Characteristics of the whole study population, and stratified by duration of diabetes in years.
Table 2.
Characteristics of the whole study population, and stratified by the HIV status of the participants.
Table 3.
Characteristics of the study population with a history of Tuberculosis (TB) and stratified by the onset of the TB episode in relation to diabetes ascertainment.
Fig 2.
Bar graph showing new diabetes cases (bars) from January 2011 to December 2017 overlaid with line plots of new Tuberculosis (solid line) and HIV (dashed line) cases in these diabetes patients in the same time period.
Fig 3.
Distribution of repeat Tuberculosis (TB) episodes in the study population before and after diabetes ascertainment.
Fig 4.
Effect of Tuberculosis ascertainment on HbA1c (%) over a 5-year period.
A. HbA1c plotted by diabetes treatment i.e. on diabetes treatment (grey circle) or not on diabetes treatment (dark-red star). B. HbA1c plotted by TB episode i.e. 1 episode (grey circle), 2 episodes (pale-green square), 3 episodes (steel-blue star) or 4 episodes (dark-red diamond).
Fig 5.
Effect of HIV ascertainment on HbA1c (%) over a 5-year period.
A. HbA1c plotted by diabetes treatment i.e. on diabetes treatment (grey circle) or not on diabetes treatment (dark-red star). B. HbA1c plotted by TB history i.e. never had TB (grey circle) or have had TB (dark-red star).
Table 4.
Pharmacy counts with last recorded HbA1c values for the whole population and stratified by duration of diabetes in years since ascertainment.